A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects

• Main Authors: Kenan Gu (Author), Dennis Ruff (Author), Cassandra Key (Author), Marissa Thompson (Author), Shoshanna Jiang (Author), Taylor Sandison (Author), Shawn Flanagan (Author)
• Format: Book
• Published: Wiley, 2022-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Rezafungin is a novel echinocandin being developed for the treatment and prevention of invasive fungal infections. The objectives of this randomized, double‐blind study in healthy adults were to determine the safety, tolerability, and pharmacokinetics of rezafungin after subcutaneous (s.c.)...